NASDAQ:CSTL Castle Biosciences Q3 2026 Earnings Date & Estimates $34.42 +0.71 (+2.11%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$34.42 +0.00 (+0.01%) As of 10/9/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Castle Biosciences is scheduled to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 2, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Castle Biosciences in Q3 2026Castle Biosciences is expected to post earnings of -$0.3544 per share on revenue of $92.26 million. In the same quarter a year earlier Castle Biosciences reported -$0.02 per share on revenue of $80.55 million. Castle Biosciences last reported on July 30, 2026, posting -$0.07 per share and beating the -$0.4070 consensus estimate. Castle Biosciences has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.3544Expected Revenue$92.26 millionPrior-Year EPS-$0.02Prior-Year Revenue$80.55 millionExpected Revenue Growth+14.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.07 (Beat by +$0.3370)Last Quarter Revenue$99.86 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Castle Biosciences Q3 2026 Earnings FAQ When does Castle Biosciences report Q3 2026 earnings? Castle Biosciences (NASDAQ:CSTL) is scheduled to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. What time is Castle Biosciences' Q3 2026 earnings call? Castle Biosciences' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Castle Biosciences? Analysts expect Castle Biosciences to post earnings of -$0.3544 per share for Q3 2026. How much revenue is Castle Biosciences expected to report? The consensus revenue estimate for Castle Biosciences is $92.26 million for Q3 2026. Castle Biosciences Earnings HeadlinesNew Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)October 9 at 12:24 PM | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Average Price Target of $42.00October 9 at 2:15 AM | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 11 at 1:00 AM | Banyan Hill Publishing (Ad)Castle Biosciences (NASDAQ:CSTL) Stock: Insider Kristen Oelschlager Sells 4,153 SharesOctober 7, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG) and Castle Biosciences (CSTL)October 3, 2026 | theglobeandmail.comCastle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 5,543 SharesOctober 3, 2026 | americanbankingnews.comSee More Castle Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Castle Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Castle Biosciences and other key companies, straight to your email. Email Address About Castle BiosciencesCastle Biosciences (NASDAQ:CSTL) is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management. The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma. Castle also offers MyPath Melanoma, which is intended to help distinguish benign from malignant melanocytic lesions, and tests for uveal melanoma and other ophthalmic cancers. Castle Biosciences has expanded beyond dermatologic oncology through products such as TissueCypher, a test designed to help predict progression risk in patients with Barrett’s esophagus. The company primarily serves physicians, hospitals and other healthcare providers in the United States. Castle Biosciences was founded in 2008 and is headquartered in Friendswood, Texas. Derek Maetzold is the company’s president and chief executive officer.View Castle Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
